You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NamePerflutren
Accession NumberDB00556  (APRD01177)
TypeSmall Molecule
GroupsApproved
DescriptionPerflutren, a diagnostic drug that is intended to be used for contrast enhancement during the indicated echocardiographic procedures, is comprised of lipid-coated microspheres filled with octafluoropropane(OFP) gas. When exposed to ultrasound waves, the microspheres resonate and "echo" strong signals back to the ultrasound machine. The difference in density between the gas-filled bubbles and the blood around them creates an increased level of contrast visible in the resulting ultrasound image. During echocardiography, activated Perflutren enhances images of the inner edges or borders of the heart, producing an improved image that may enable physicians to better diagnose patients.
Structure
Thumb
Synonyms
1,1,1,2,2,3,3,3-Octafluoropropane
Definity
FC 218
Freon 218
Octafluoropropane
Octafluorpropan
Oktafluorpropan
Perfluoropropane
Perflutren
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Definityinjection, suspension6.52 mg/mLintravenousLantheus Medical Imaging, Inc.2001-07-31Not applicableUs
Definitysuspension150 mclintravenousLantheus Mi Canada Inc2002-02-16Not applicableCanada
LuminitySolution for dispersion for injection or infusion150 μl / mlIntravenous useLantheus Mi Uk Ltd.2006-09-20Not applicableEu
LuminitySolution for dispersion for injection or infusion150 μl / mlIntravenous useLantheus Mi Uk Ltd.2006-09-20Not applicableEu
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIICK0N3WH0SR
CAS number76-19-7
WeightAverage: 188.0193
Monoisotopic: 187.98722564
Chemical FormulaC3F8
InChI KeyInChIKey=QYSGYZVSCZSLHT-UHFFFAOYSA-N
InChI
InChI=1S/C3F8/c4-1(5,2(6,7)8)3(9,10)11
IUPAC Name
octafluoropropane
SMILES
FC(F)(F)C(F)(F)C(F)(F)F
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as organofluorides. These are compounds containing a chemical bond between a carbon atom and a fluorine atom.
KingdomOrganic compounds
Super ClassOrganohalogen compounds
ClassOrganofluorides
Sub ClassNot Available
Direct ParentOrganofluorides
Alternative Parents
Substituents
  • Hydrocarbon derivative
  • Organofluoride
  • Alkyl halide
  • Alkyl fluoride
  • Aliphatic acyclic compound
Molecular FrameworkAliphatic acyclic compounds
External Descriptors
Pharmacology
IndicationUsed as an ultrasound contrast imaging in cardiology and radiology.
PharmacodynamicsPerflutren, a diagnostic drug that is intended to be used for contrast enhancement during the indicated echocardiographic procedures, comprised of lipid-coated microspheres filled with octafluoropropane(OFP) gas. It provide contrast enhancement of the endocardial borders during echocardiography. The perflutren lipid microspheres exhibit lower acoustic impedance than blood and enhance the intrinsic backscatter of blood.
Mechanism of actionPerflutren is comprised of gas-filled microspheres that are injected or infused into the body. When exposed to ultrasound waves, the microspheres resonate and "echo" strong signals back to the ultrasound machine. The difference in density between the gas-filled bubbles and the blood around them creates an increased level of contrast visible in the resulting ultrasound image. During echocardiography, activated Perflutren enhances images of the inner edges or borders of the heart, producing an improved image that may enable physicians to better diagnose patients.
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

OFP is not metabolized. The phospholipid components of the microspheres are thought to be metabolized to free fatty acids.

Route of eliminationNot Available
Half lifeThe mean half-life of OFP in blood 1.9 minutes
ClearanceNot Available
ToxicityThere is new temporal evidence that perflutren may be associated with new-onset seizure activity following perflutren microbubble contrast injection during dobutamine-atropine stress echocardiography. [PMID: 23432576]
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9954
Blood Brain Barrier+0.9907
Caco-2 permeable+0.6518
P-glycoprotein substrateNon-substrate0.8894
P-glycoprotein inhibitor INon-inhibitor0.9583
P-glycoprotein inhibitor IINon-inhibitor0.9396
Renal organic cation transporterNon-inhibitor0.9256
CYP450 2C9 substrateNon-substrate0.865
CYP450 2D6 substrateSubstrate0.5549
CYP450 3A4 substrateNon-substrate0.7591
CYP450 1A2 substrateNon-inhibitor0.6831
CYP450 2C9 inhibitorNon-inhibitor0.8595
CYP450 2D6 inhibitorNon-inhibitor0.9581
CYP450 2C19 inhibitorNon-inhibitor0.8397
CYP450 3A4 inhibitorNon-inhibitor0.9509
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9136
Ames testNon AMES toxic0.9656
CarcinogenicityCarcinogens 0.6661
BiodegradationNot ready biodegradable0.944
Rat acute toxicity1.6879 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9796
hERG inhibition (predictor II)Non-inhibitor0.9174
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Lantheus medical imaging inc
Packagers
Dosage forms
FormRouteStrength
Injection, suspensionintravenous6.52 mg/mL
Suspensionintravenous150 mcl
Solution for dispersion for injection or infusionIntravenous use150 μl / ml
Prices
Unit descriptionCostUnit
Optison vial56.16USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2107466 No2001-07-032012-03-18Canada
CA2256592 No2010-06-012017-06-16Canada
US6033645 No1996-06-192016-06-19Us
US6146657 No1992-12-222009-12-22Us
US8658205 No1999-04-202019-04-20Us
US8685441 No1999-01-132019-01-13Us
Properties
StateLiquid
Experimental Properties
PropertyValueSource
melting point-147.6 °CPhysProp
boiling point-36.6 °CPhysProp
water solubility5.7 mg/L (at 15 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP3Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.146 mg/mLALOGPS
logP2.96ALOGPS
logP2.78ChemAxon
logS-3.1ALOGPS
Physiological Charge0ChemAxon
Hydrogen Acceptor Count0ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area0 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity17.54 m3·mol-1ChemAxon
Polarizability7.1 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (7.49 KB)
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

James L. Webster, Steven H. Swearingen, Douglas W. Bruhnke, Leo E. Manzer, Elrey L. McCann, “Synthesis of perfluoropropane.” U.S. Patent US5220083, issued August, 1967.

US5220083
General References
  1. Quinones A, Benenstein R, Saric M: New-onset seizure after perflutren microbubble injection during dobutamine stress echocardiography. Echocardiography. 2013 Apr;30(4):E95-7. doi: 10.1111/echo.12149. Epub 2013 Feb 22. [PubMed:23432576 ]
External Links
ATC CodesNot Available
AHFS Codes
  • 92:00.00
PDB EntriesNot Available
FDA labelDownload (584 KB)
MSDSDownload (64 KB)
Interactions
Drug Interactions
Drug
AlfuzosinAlfuzosin may increase the QTc-prolonging activities of Perflutren.
AmantadineAmantadine may increase the QTc-prolonging activities of Perflutren.
AmiodaronePerflutren may increase the QTc-prolonging activities of Amiodarone.
AmitriptylineAmitriptyline may increase the QTc-prolonging activities of Perflutren.
AmoxapineAmoxapine may increase the QTc-prolonging activities of Perflutren.
AnagrelidePerflutren may increase the QTc-prolonging activities of Anagrelide.
ApomorphineApomorphine may increase the QTc-prolonging activities of Perflutren.
ArformoterolArformoterol may increase the QTc-prolonging activities of Perflutren.
AripiprazoleAripiprazole may increase the QTc-prolonging activities of Perflutren.
Arsenic trioxidePerflutren may increase the QTc-prolonging activities of Arsenic trioxide.
ArtemetherPerflutren may increase the QTc-prolonging activities of Artemether.
AsenapinePerflutren may increase the QTc-prolonging activities of Asenapine.
AtazanavirAtazanavir may increase the QTc-prolonging activities of Perflutren.
AtomoxetineAtomoxetine may increase the QTc-prolonging activities of Perflutren.
AzithromycinAzithromycin may increase the QTc-prolonging activities of Perflutren.
BedaquilinePerflutren may increase the QTc-prolonging activities of Bedaquiline.
BortezomibBortezomib may increase the QTc-prolonging activities of Perflutren.
BuserelinBuserelin may increase the QTc-prolonging activities of Perflutren.
CeritinibPerflutren may increase the QTc-prolonging activities of Ceritinib.
ChloroquinePerflutren may increase the QTc-prolonging activities of Chloroquine.
ChlorpromazineChlorpromazine may increase the QTc-prolonging activities of Perflutren.
CiprofloxacinCiprofloxacin may increase the QTc-prolonging activities of Perflutren.
CisapridePerflutren may increase the QTc-prolonging activities of Cisapride.
CitalopramPerflutren may increase the QTc-prolonging activities of Citalopram.
ClarithromycinPerflutren may increase the QTc-prolonging activities of Clarithromycin.
ClomipramineClomipramine may increase the QTc-prolonging activities of Perflutren.
ClozapineClozapine may increase the QTc-prolonging activities of Perflutren.
CrizotinibPerflutren may increase the QTc-prolonging activities of Crizotinib.
DabrafenibDabrafenib may increase the QTc-prolonging activities of Perflutren.
DasatinibDasatinib may increase the QTc-prolonging activities of Perflutren.
DegarelixDegarelix may increase the QTc-prolonging activities of Perflutren.
DesfluraneDesflurane may increase the QTc-prolonging activities of Perflutren.
DesipramineDesipramine may increase the QTc-prolonging activities of Perflutren.
DiphenhydramineDiphenhydramine may increase the QTc-prolonging activities of Perflutren.
DisopyramidePerflutren may increase the QTc-prolonging activities of Disopyramide.
DofetilidePerflutren may increase the QTc-prolonging activities of Dofetilide.
DolasetronPerflutren may increase the QTc-prolonging activities of Dolasetron.
DomperidonePerflutren may increase the QTc-prolonging activities of Domperidone.
DoxepinDoxepin may increase the QTc-prolonging activities of Perflutren.
DronedaronePerflutren may increase the QTc-prolonging activities of Dronedarone.
DroperidolDroperidol may increase the QTc-prolonging activities of Perflutren.
EliglustatPerflutren may increase the QTc-prolonging activities of Eliglustat.
EribulinEribulin may increase the QTc-prolonging activities of Perflutren.
ErythromycinErythromycin may increase the QTc-prolonging activities of Perflutren.
EscitalopramPerflutren may increase the QTc-prolonging activities of Escitalopram.
EzogabineEzogabine may increase the QTc-prolonging activities of Perflutren.
FamotidineFamotidine may increase the QTc-prolonging activities of Perflutren.
FelbamateFelbamate may increase the QTc-prolonging activities of Perflutren.
FingolimodFingolimod may increase the QTc-prolonging activities of Perflutren.
FlecainidePerflutren may increase the QTc-prolonging activities of Flecainide.
FluconazoleFluconazole may increase the QTc-prolonging activities of Perflutren.
FluoxetinePerflutren may increase the QTc-prolonging activities of Fluoxetine.
FlupentixolPerflutren may increase the QTc-prolonging activities of Flupentixol.
FormoterolFormoterol may increase the QTc-prolonging activities of Perflutren.
FoscarnetFoscarnet may increase the QTc-prolonging activities of Perflutren.
Gadobenic acidPerflutren may increase the QTc-prolonging activities of Gadobenic acid.
GalantamineGalantamine may increase the QTc-prolonging activities of Perflutren.
GemifloxacinPerflutren may increase the QTc-prolonging activities of Gemifloxacin.
GoserelinGoserelin may increase the QTc-prolonging activities of Perflutren.
GranisetronPerflutren may increase the QTc-prolonging activities of Granisetron.
HaloperidolHaloperidol may increase the QTc-prolonging activities of Perflutren.
HistrelinHistrelin may increase the QTc-prolonging activities of Perflutren.
HydroxyzineHydroxyzine may increase the QTc-prolonging activities of Perflutren.
IbandronateIbandronate may increase the QTc-prolonging activities of Perflutren.
IbutilidePerflutren may increase the QTc-prolonging activities of Ibutilide.
IloperidonePerflutren may increase the QTc-prolonging activities of Iloperidone.
ImipramineImipramine may increase the QTc-prolonging activities of Perflutren.
IndacaterolIndacaterol may increase the QTc-prolonging activities of Perflutren.
IndapamideIndapamide may increase the QTc-prolonging activities of Perflutren.
IsofluraneIsoflurane may increase the QTc-prolonging activities of Perflutren.
IsradipineIsradipine may increase the QTc-prolonging activities of Perflutren.
ItraconazoleItraconazole may increase the QTc-prolonging activities of Perflutren.
IvabradineIvabradine may increase the QTc-prolonging activities of Perflutren.
KetoconazoleKetoconazole may increase the QTc-prolonging activities of Perflutren.
LapatinibLapatinib may increase the QTc-prolonging activities of Perflutren.
LenvatinibPerflutren may increase the QTc-prolonging activities of Lenvatinib.
LeuprolideLeuprolide may increase the QTc-prolonging activities of Perflutren.
LevofloxacinPerflutren may increase the QTc-prolonging activities of Levofloxacin.
LithiumLithium may increase the QTc-prolonging activities of Perflutren.
LopinavirPerflutren may increase the QTc-prolonging activities of Lopinavir.
LumefantrinePerflutren may increase the QTc-prolonging activities of Lumefantrine.
MaprotilineMaprotiline may increase the QTc-prolonging activities of Perflutren.
MefloquineMefloquine may increase the QTc-prolonging activities of Perflutren.
MethadoneMethadone may increase the QTc-prolonging activities of Perflutren.
MethotrimeprazineMethotrimeprazine may increase the QTc-prolonging activities of Perflutren.
MetoclopramideMetoclopramide may increase the QTc-prolonging activities of Perflutren.
MetronidazoleMetronidazole may increase the QTc-prolonging activities of Perflutren.
MifepristoneMifepristone may increase the QTc-prolonging activities of Perflutren.
MirabegronMirabegron may increase the QTc-prolonging activities of Perflutren.
MirtazapineMirtazapine may increase the QTc-prolonging activities of Perflutren.
MoexiprilMoexipril may increase the QTc-prolonging activities of Perflutren.
MoxifloxacinMoxifloxacin may increase the QTc-prolonging activities of Perflutren.
NelfinavirNelfinavir may increase the QTc-prolonging activities of Perflutren.
NicardipineNicardipine may increase the QTc-prolonging activities of Perflutren.
NilotinibPerflutren may increase the QTc-prolonging activities of Nilotinib.
NorfloxacinNorfloxacin may increase the QTc-prolonging activities of Perflutren.
NortriptylineNortriptyline may increase the QTc-prolonging activities of Perflutren.
OctreotideOctreotide may increase the QTc-prolonging activities of Perflutren.
OfloxacinPerflutren may increase the QTc-prolonging activities of Ofloxacin.
OlanzapineOlanzapine may increase the QTc-prolonging activities of Perflutren.
OlodaterolOlodaterol may increase the QTc-prolonging activities of Perflutren.
OndansetronPerflutren may increase the QTc-prolonging activities of Ondansetron.
OxytocinOxytocin may increase the QTc-prolonging activities of Perflutren.
PaliperidonePerflutren may increase the QTc-prolonging activities of Paliperidone.
PanobinostatPerflutren may increase the QTc-prolonging activities of Panobinostat.
ParoxetineParoxetine may increase the QTc-prolonging activities of Perflutren.
PasireotidePasireotide may increase the QTc-prolonging activities of Perflutren.
PazopanibPerflutren may increase the QTc-prolonging activities of Pazopanib.
PentamidinePerflutren may increase the QTc-prolonging activities of Pentamidine.
PimozidePerflutren may increase the QTc-prolonging activities of Pimozide.
PosaconazolePosaconazole may increase the QTc-prolonging activities of Perflutren.
PrimaquinePerflutren may increase the QTc-prolonging activities of Primaquine.
ProcainamidePerflutren may increase the QTc-prolonging activities of Procainamide.
PromazinePromazine may increase the QTc-prolonging activities of Perflutren.
PromethazinePromethazine may increase the QTc-prolonging activities of Perflutren.
PropafenonePerflutren may increase the QTc-prolonging activities of Propafenone.
PropofolPropofol may increase the QTc-prolonging activities of Perflutren.
ProtriptylineProtriptyline may increase the QTc-prolonging activities of Perflutren.
QuetiapinePerflutren may increase the QTc-prolonging activities of Quetiapine.
QuinidinePerflutren may increase the QTc-prolonging activities of Quinidine.
QuininePerflutren may increase the QTc-prolonging activities of Quinine.
RanolazineRanolazine may increase the QTc-prolonging activities of Perflutren.
RilpivirineRilpivirine may increase the QTc-prolonging activities of Perflutren.
RisperidoneRisperidone may increase the QTc-prolonging activities of Perflutren.
RitonavirRitonavir may increase the QTc-prolonging activities of Perflutren.
SalbutamolSalbutamol may increase the QTc-prolonging activities of Perflutren.
SalmeterolSalmeterol may increase the QTc-prolonging activities of Perflutren.
SaquinavirPerflutren may increase the QTc-prolonging activities of Saquinavir.
SertralineSertraline may increase the QTc-prolonging activities of Perflutren.
SevofluraneSevoflurane may increase the QTc-prolonging activities of Perflutren.
SolifenacinSolifenacin may increase the QTc-prolonging activities of Perflutren.
SorafenibSorafenib may increase the QTc-prolonging activities of Perflutren.
SotalolPerflutren may increase the QTc-prolonging activities of Sotalol.
SulfamethoxazoleSulfamethoxazole may increase the QTc-prolonging activities of Perflutren.
SulfisoxazoleSulfisoxazole may increase the QTc-prolonging activities of Perflutren.
SunitinibSunitinib may increase the QTc-prolonging activities of Perflutren.
TamoxifenTamoxifen may increase the QTc-prolonging activities of Perflutren.
TelavancinPerflutren may increase the QTc-prolonging activities of Telavancin.
TelithromycinPerflutren may increase the QTc-prolonging activities of Telithromycin.
TerbutalineTerbutaline may increase the QTc-prolonging activities of Perflutren.
TetrabenazinePerflutren may increase the QTc-prolonging activities of Tetrabenazine.
ThioridazinePerflutren may increase the QTc-prolonging activities of Thioridazine.
ThiothixeneThiothixene may increase the QTc-prolonging activities of Perflutren.
TizanidineTizanidine may increase the QTc-prolonging activities of Perflutren.
TolterodineTolterodine may increase the QTc-prolonging activities of Perflutren.
ToremifenePerflutren may increase the QTc-prolonging activities of Toremifene.
TrazodoneTrazodone may increase the QTc-prolonging activities of Perflutren.
TreprostinilTreprostinil may increase the QTc-prolonging activities of Perflutren.
TrimethoprimTrimethoprim may increase the QTc-prolonging activities of Perflutren.
TrimipramineTrimipramine may increase the QTc-prolonging activities of Perflutren.
TriptorelinTriptorelin may increase the QTc-prolonging activities of Perflutren.
VandetanibPerflutren may increase the QTc-prolonging activities of Vandetanib.
VardenafilVardenafil may increase the QTc-prolonging activities of Perflutren.
VemurafenibPerflutren may increase the QTc-prolonging activities of Vemurafenib.
VenlafaxineVenlafaxine may increase the QTc-prolonging activities of Perflutren.
VilanterolVilanterol may increase the QTc-prolonging activities of Perflutren.
VoriconazoleVoriconazole may increase the QTc-prolonging activities of Perflutren.
VorinostatVorinostat may increase the QTc-prolonging activities of Perflutren.
ZiprasidonePerflutren may increase the QTc-prolonging activities of Ziprasidone.
ZuclopenthixolPerflutren may increase the QTc-prolonging activities of Zuclopenthixol.
Food InteractionsNot Available
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 24, 2016 02:15